Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2026-05-06 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
自有闲置资金委托理财进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the progress of entrusted financial management of its own idle funds. It details the authorization, amounts, types, and terms of financial products purchased with the company's idle funds, including bank wealth management products and structured deposits. The document includes disclosures required by the Beijing Stock Exchange listing rules, risk control measures, and a summary of ongoing and matured entrusted financial products. There is no indication that this is a full financial report, audit report, or earnings release. It is not a regulatory filing or certification letter but a specific update on the company's capital management activities related to financing and investment of idle funds. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive details about financing activities, not just an announcement of a report publication or a brief notice. Confidence is high due to the detailed financial product information and the nature of the announcement.
2026-05-06 Chinese
[临时公告]德源药业:公司章程
Governance Information Classification · 100% confidence The document is titled "江苏德源药业股份有限公司章程" which translates to "Articles of Association of Jiangsu Deyuan Pharmaceutical Co., Ltd." It contains detailed chapters on company organization, shareholder rights, board of directors, management, financial accounting, profit distribution, auditing, information disclosure, and investor relations management. The content is focused on the company's internal rules, governance structure, shareholder meetings, board responsibilities, and compliance with laws and regulations. There is no indication that this is an annual report, audit report, earnings release, or any other financial or regulatory filing. Instead, it is a governance document outlining the company's articles of association, which is a key governance information document. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content support this classification with high confidence.
2026-03-25 Chinese
持股5%以上股东拟减持股份的预披露公告
Major Shareholding Notification Classification · 100% confidence The document is a pre-disclosure announcement regarding a shareholder holding more than 5% of shares planning to reduce their holdings. It details the shareholder's identity, the number and percentage of shares to be reduced, the method and timing of the reduction, and compliance with relevant laws and regulations. It also includes risk disclosures related to the share reduction plan. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory announcement about a planned shareholding reduction by a major shareholder, which fits the definition of a Major Shareholding Notification (MRQ). The document length is 2468 characters, which is typical for such announcements. Therefore, the correct classification is MRQ with high confidence.
2026-03-22 Chinese
关于瑞舒伐他汀依折麦布片（I）获国家药监局签发药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the approval and issuance of a drug registration certificate by the National Medical Products Administration (NMPA) for a specific pharmaceutical product. It details the drug's specifications, regulatory approval, market impact, and risk warnings. The document is short (1350 characters) and serves as an official announcement of a regulatory approval event rather than a financial report, management change, or other corporate filing. It does not contain financial data, management discussion, or shareholder voting results. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2026-03-15 Chinese
投资者关系活动记录表
Call Transcript Classification · 90% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record". It details a performance explanation meeting held on March 11, 2026, discussing the company's 2025 annual operating results, innovation drug progress, drug approvals, and production base projects. The content is a Q&A format typical of an earnings or performance explanation session rather than a formal earnings release or full financial report. The document length is 2411 characters, which is relatively short and focused on investor communication about performance. This matches the characteristics of a Call Transcript (CT) or an Investor Presentation (IP). However, since it is a record of an "业绩说明会" (performance explanation meeting) with Q&A, it aligns best with a Call Transcript (CT) category rather than a presentation or a brief earnings release. Therefore, the document is classified as a Call Transcript (CT).
2026-03-11 Chinese
关于2025年年度股东会增加临时提案的公告
AGM Information Classification · 95% confidence The document is an announcement regarding the addition of a temporary proposal to the 2025 Annual General Meeting (AGM) of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the meeting date, proposal submission, and agenda items for the AGM. It does not contain the full annual report or financial statements but rather information about the AGM agenda and proposals. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM or related announcements about the AGM agenda.
2026-03-11 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.